PL2081572T3 - Benzimidazolowe związki antagonistyczne wobec receptora kannabinoidowego zawierające podstawioną grupę heterocykliczną - Google Patents
Benzimidazolowe związki antagonistyczne wobec receptora kannabinoidowego zawierające podstawioną grupę heterocyklicznąInfo
- Publication number
- PL2081572T3 PL2081572T3 PL07786974T PL07786974T PL2081572T3 PL 2081572 T3 PL2081572 T3 PL 2081572T3 PL 07786974 T PL07786974 T PL 07786974T PL 07786974 T PL07786974 T PL 07786974T PL 2081572 T3 PL2081572 T3 PL 2081572T3
- Authority
- PL
- Poland
- Prior art keywords
- heterocyclic group
- substituted heterocyclic
- cannabinoid agonists
- compounds
- bearing
- Prior art date
Links
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 229930003827 cannabinoid Natural products 0.000 title 1
- 239000003557 cannabinoid Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 abstract 2
- 108050007331 Cannabinoid receptor Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 238000001311 chemical methods and process Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06116564 | 2006-07-04 | ||
| PCT/EP2007/056619 WO2008003665A1 (en) | 2006-07-04 | 2007-07-02 | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group |
| EP07786974A EP2081572B1 (en) | 2006-07-04 | 2007-07-02 | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2081572T3 true PL2081572T3 (pl) | 2010-07-30 |
Family
ID=37453123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07786974T PL2081572T3 (pl) | 2006-07-04 | 2007-07-02 | Benzimidazolowe związki antagonistyczne wobec receptora kannabinoidowego zawierające podstawioną grupę heterocykliczną |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8524757B2 (pl) |
| EP (1) | EP2081572B1 (pl) |
| JP (1) | JP5345528B2 (pl) |
| KR (1) | KR20090024789A (pl) |
| CN (1) | CN101621998B (pl) |
| AT (1) | ATE459352T1 (pl) |
| AU (1) | AU2007271241A1 (pl) |
| BR (1) | BRPI0714199A2 (pl) |
| CA (1) | CA2654246A1 (pl) |
| CY (1) | CY1110342T1 (pl) |
| DE (1) | DE602007005160D1 (pl) |
| DK (1) | DK2081572T3 (pl) |
| EA (1) | EA200970080A1 (pl) |
| ES (1) | ES2341188T3 (pl) |
| IL (1) | IL196289A0 (pl) |
| MX (1) | MX2009000149A (pl) |
| PL (1) | PL2081572T3 (pl) |
| PT (1) | PT2081572E (pl) |
| SI (1) | SI2081572T1 (pl) |
| WO (1) | WO2008003665A1 (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103880827B (zh) | 2004-07-15 | 2017-01-04 | 阿尔巴尼分子研究公司 | 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用 |
| US7951829B2 (en) * | 2006-05-03 | 2011-05-31 | Janssen Pharmaceutica Nv | Benzimidazole modulators of VR1 |
| ES2548764T3 (es) * | 2007-03-30 | 2015-10-20 | Janssen Pharmaceutica N.V. | Agonistas de cannabinoides de bencimidazol |
| ES2574130T3 (es) * | 2007-12-17 | 2016-06-15 | Janssen Pharmaceutica, N.V. | Bencimidazoles sustituidos con fluoroalquilo como agonistas cannabinoides |
| AR071997A1 (es) * | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| BRPI1007202A2 (pt) * | 2009-01-22 | 2016-02-23 | Raqualia Pharma Inc | composto de fórmula (i), composição farmacêutica, método para tratamento de condição mediada pela atividade do receptor cb2 em um indivíduo mamífero e uso de composto de fórmula (i) |
| EP2429295B1 (en) | 2009-05-12 | 2013-12-25 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| BR112012001558A2 (pt) | 2009-07-23 | 2016-03-08 | Bayer Cropscience Ag | alcoxienonas e enaminocetonas e um processo para a sua preparação |
| SG10201404925TA (en) | 2009-08-28 | 2014-10-30 | Arena Pharm Inc | Cannabinoid receptor modulators |
| EP3395812B8 (en) | 2011-02-25 | 2022-11-02 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators) |
| WO2012116277A1 (en) | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| CN103492369B (zh) | 2011-02-25 | 2019-03-29 | 艾尼纳制药公司 | 大麻素受体调节剂 |
| AU2017260706B2 (en) | 2016-05-04 | 2023-05-11 | Inmed Pharmaceuticals Inc. | Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders |
| WO2018208848A1 (en) | 2017-05-08 | 2018-11-15 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of visceral pain |
| WO2019056123A1 (en) | 2017-09-22 | 2019-03-28 | Inmed Pharmaceuticals Inc. | TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF PAIN |
| WO2025090587A1 (en) | 2023-10-23 | 2025-05-01 | Inmed Pharmaceuticals Inc. | Cannabinoids compounds and their use in the treatment of neuronal disorders |
| WO2025090133A1 (en) | 2023-10-23 | 2025-05-01 | Inmed Pharmaceuticals Inc. | Compositions and methods for use of cannabinol compounds in neuroprotection |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08272028A (ja) * | 1995-03-30 | 1996-10-18 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料およびその製造方法 |
| JPH08283590A (ja) | 1995-04-20 | 1996-10-29 | Fuji Photo Film Co Ltd | シアニン化合物および染料組成物 |
| JP2000026430A (ja) * | 1998-07-02 | 2000-01-25 | Taisho Pharmaceut Co Ltd | ２、５、６−置換ベンズイミダゾール化合物誘導体 |
| SE0101387D0 (sv) * | 2001-04-20 | 2001-04-20 | Astrazeneca Ab | Novel compounds |
| ES2318556T3 (es) * | 2004-11-02 | 2009-05-01 | Pfizer, Inc. | Derivados de sulfonil bencimidazol. |
| TW200808769A (en) * | 2006-04-18 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
-
2007
- 2007-07-02 BR BRPI0714199-8A patent/BRPI0714199A2/pt not_active Application Discontinuation
- 2007-07-02 DK DK07786974.1T patent/DK2081572T3/da active
- 2007-07-02 AT AT07786974T patent/ATE459352T1/de active
- 2007-07-02 EP EP07786974A patent/EP2081572B1/en active Active
- 2007-07-02 DE DE602007005160T patent/DE602007005160D1/de active Active
- 2007-07-02 WO PCT/EP2007/056619 patent/WO2008003665A1/en not_active Ceased
- 2007-07-02 PT PT07786974T patent/PT2081572E/pt unknown
- 2007-07-02 KR KR1020097000568A patent/KR20090024789A/ko not_active Withdrawn
- 2007-07-02 US US12/307,512 patent/US8524757B2/en not_active Expired - Fee Related
- 2007-07-02 CA CA002654246A patent/CA2654246A1/en not_active Abandoned
- 2007-07-02 CN CN2007800230162A patent/CN101621998B/zh not_active Expired - Fee Related
- 2007-07-02 MX MX2009000149A patent/MX2009000149A/es not_active Application Discontinuation
- 2007-07-02 SI SI200730225T patent/SI2081572T1/sl unknown
- 2007-07-02 JP JP2009517236A patent/JP5345528B2/ja not_active Expired - Fee Related
- 2007-07-02 EA EA200970080A patent/EA200970080A1/ru unknown
- 2007-07-02 AU AU2007271241A patent/AU2007271241A1/en not_active Abandoned
- 2007-07-02 ES ES07786974T patent/ES2341188T3/es active Active
- 2007-07-02 PL PL07786974T patent/PL2081572T3/pl unknown
-
2008
- 2008-12-31 IL IL196289A patent/IL196289A0/en unknown
-
2010
- 2010-06-03 CY CY20101100493T patent/CY1110342T1/el unknown
-
2013
- 2013-08-06 US US13/959,980 patent/US9284303B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| SI2081572T1 (sl) | 2010-06-30 |
| EP2081572B1 (en) | 2010-03-03 |
| IL196289A0 (en) | 2009-09-22 |
| EP2081572A1 (en) | 2009-07-29 |
| PT2081572E (pt) | 2010-05-17 |
| JP2009541453A (ja) | 2009-11-26 |
| KR20090024789A (ko) | 2009-03-09 |
| DK2081572T3 (da) | 2010-06-07 |
| MX2009000149A (es) | 2009-01-23 |
| AU2007271241A1 (en) | 2008-01-10 |
| BRPI0714199A2 (pt) | 2012-12-25 |
| WO2008003665A1 (en) | 2008-01-10 |
| ATE459352T1 (de) | 2010-03-15 |
| CY1110342T1 (el) | 2015-01-14 |
| DE602007005160D1 (de) | 2010-04-15 |
| US20130324529A1 (en) | 2013-12-05 |
| ES2341188T3 (es) | 2010-06-16 |
| EA200970080A1 (ru) | 2009-06-30 |
| HK1139058A1 (en) | 2010-09-10 |
| US9284303B2 (en) | 2016-03-15 |
| CA2654246A1 (en) | 2008-01-10 |
| JP5345528B2 (ja) | 2013-11-20 |
| US8524757B2 (en) | 2013-09-03 |
| CN101621998A (zh) | 2010-01-06 |
| US20090312339A1 (en) | 2009-12-17 |
| CN101621998B (zh) | 2013-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL196289A0 (en) | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group | |
| ZA202306748B (en) | Glp-1r receptor agonist compound and use thereof | |
| WO2009071631A3 (en) | Dibenzoazepine and dibenzooxazepine trpa1 agonists | |
| ATE482210T1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
| UA99132C2 (ru) | Производные дикарбоновых кислот как агонисты рецепторов s1p1 | |
| ATE533762T1 (de) | Chinolin- oder isochinolinsubstituierte p2x7- antagonisten | |
| HRP20090235B1 (hr) | Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d | |
| PT1716152E (pt) | Compostos heterocíclicos fundidos e sua utilização como antagonistas do receptor metabotrópico para o tratamento de distúrbios gastrointestinais | |
| EA200970967A1 (ru) | Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip) | |
| NZ590650A (en) | Buprenorphine analogs | |
| ATE445609T1 (de) | Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen | |
| EP1861399A4 (en) | CGRP RECEPTOR ANTAGONISTS | |
| TW200637874A (en) | Peptides with neuropeptide-2 receptor (Y2R) agonist activity | |
| NO20091052L (no) | Diaryleterderivater og anvendelser derav | |
| JO3126B1 (ar) | مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1 | |
| ECSP088948A (es) | 4-metil-1h-pirrol-2-carboxamidas 1,3-disustituidas y su uso para la producción de medicamentos | |
| MX2009010374A (es) | Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos. | |
| MX2011013869A (es) | Agentes antihelminticos y su uso. | |
| TW200736189A (en) | Indene derivatives, their preparation and use as medicaments | |
| EA200802104A1 (ru) | Применение композиций, содержащих антагонисты каппа-опиоидных рецепторов, для лечения диссоциативных расстройств | |
| MX2008002805A (es) | Derivados de carboxamida como antagonistas del receptor muscarinico. | |
| DK2201002T3 (da) | 5-HT7-receptorantagonister | |
| TW200714603A (en) | Acylaminobicyclic heteroaromatic compounds and uses thereof | |
| DE602006014097D1 (de) | Cgrp-rezeptorantagonisten | |
| ATE461172T1 (de) | Azetidinderivate als antagonisten des muskarinrezeptors |